Tumor-associated macrophages in glioblastoma: implications for immunotherapy
Glioblastoma, IDH-wildtype, CNS WHO grade 4 (GBM) is the most aggressive primary malignant brain tumor in adults, with a median overall survival of approximately 15 months despite maximal surgical resection, radiotherapy, and chemotherapy with temozolo…